Recommendations by the Spanish Society of Hospital Pharmacy, the Spanish Society of Oncology Nursing and the Spanish Society of Medical Oncology for the safe management of antineoplastic medication in cancer patients.


Journal

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119

Informations de publication

Date de publication:
Apr 2019
Historique:
received: 16 07 2018
accepted: 05 09 2018
pubmed: 10 10 2018
medline: 25 7 2019
entrez: 10 10 2018
Statut: ppublish

Résumé

To define recommendations that permit safe management of antineoplastic medication, minimise medication errors and improve the safety of cancer patients undergoing treatment. By reviewing the literature and consulting the websites of various health organisations and agencies, an expert committee from the Spanish Society of Hospital Pharmacy and the Spanish Society of Medical Oncology defined a set of safe practices covering all stages of providing cancer therapy to patients. The Spanish Society of Oncology Nursing revised and endorsed the final list. In total, 68 recommendations arranged in five sections were defined. They include issues concerning the training of health professionals, the technological resources needed, treatment planning, informing the patient and his/her family, the processes of prescribing, preparing, dispensing and administering cancer therapy (orally, parenterally or intrathecally), assessing patient adherence and treatment toxicity. It is essential for healthcare establishments to implement specific measures designed to prevent medication errors, in order to ensure the safety of cancer patients treated with antineoplastic medication.

Identifiants

pubmed: 30298467
doi: 10.1007/s12094-018-1945-x
pii: 10.1007/s12094-018-1945-x
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article Practice Guideline

Langues

eng

Pagination

467-478

Références

Pharm World Sci. 2008 Apr;30(2):161-8
pubmed: 17906939
Int J Cancer. 2009 Feb 1;124(3):722-8
pubmed: 18989899
Eur J Cancer Care (Engl). 2010 May;19(3):285-92
pubmed: 19708929
Oncol Nurs Forum. 2009 Nov;36(6):651-8
pubmed: 19887353
J Oncol Pharm Pract. 2011 Sep;17(3):252-9
pubmed: 20525750
Farm Hosp. 2011 Jul-Aug;35(4):197-203
pubmed: 20637672
J Oncol Pharm Pract. 2011 Dec;17(4):409-24
pubmed: 20876081
Asia Pac J Clin Oncol. 2010 Sep;6(3):220-37
pubmed: 20887505
J Oncol Pract. 2011 Jan;7(1):7-12
pubmed: 21532802
J Oncol Pract. 2012 Jan;8(1):2-6
pubmed: 22548003
Eur J Oncol Nurs. 2013 Apr;17(2):228-35
pubmed: 22898657
Clin J Oncol Nurs. 2012 Dec;16(6):E192-7
pubmed: 23178361
J Oncol Pract. 2013 Mar;9(2 Suppl):14s-8s
pubmed: 23914147
J Oncol Pract. 2013 Mar;9(2 Suppl):5s-13s
pubmed: 23914148
J Oncol Pract. 2014 Mar;10(2):e14-25
pubmed: 24254406
J Oncol Pharm Pract. 2014 Dec;20(6):445-60
pubmed: 24356802
Curr Oncol. 2014 Aug;21(4):e604-12
pubmed: 25089110
J Oncol Pharm Pract. 2016 Feb;22(1):142-50
pubmed: 25316612
J Oncol Pharm Pract. 2015 Feb;21(1):26-35
pubmed: 25361598
Curr Oncol. 2015 Feb;22(1):e27-37
pubmed: 25684994
Am J Health Syst Pharm. 2015 Apr 15;72(8):e6-e35
pubmed: 25825193
Clin J Oncol Nurs. 2015 Jun;19(3 Suppl):41-6
pubmed: 26030392
J Oncol Pract. 2016 Feb;12(2):168-9; e180-7
pubmed: 26420888
Expert Opin Drug Saf. 2016;15(4):427-35
pubmed: 26854363
J Oncol Pharm Pract. 2017 Jul;23(5):338-343
pubmed: 27208015
Asian Pac J Cancer Prev. 2016;17(4):2329-36
pubmed: 27221940
Tumori. 2016 Aug 29;102(Suppl 1):2-6
pubmed: 27581594
Oncol Nurs Forum. ;44(1):31-43
pubmed: 28067033
Clin Transl Oncol. 2017 Mar;19(3):269-272
pubmed: 28083756
Farm Hosp. 2017 Jul 01;41(4):488-496
pubmed: 28683700
J Oncol Pract. 2008 Sep;4(5):254-257
pubmed: 29452528

Auteurs

R Vera (R)

Servicio de Oncología Médica, Complejo Hospitalario de Navarra, Calle Irunlarrea, 3, 31008, Pamplona, Navarra, Spain. ruth.vera.garcia@cfnavarra.es.

M J Otero (MJ)

Instituto para el Uso Seguro de los Medicamentos (ISMP-España), Servicio de Farmacia Hospitalaria, Hospital Universitario de Salamanca, Salamanca, Spain.

F Ayala de la Peña (F)

Servicio de Hematología y Oncología Médica, Hospital General Universitario Morales Meseguer, Murcia, Spain.

C González-Pérez (C)

Servicio de Farmacia Hospitalaria, Hospital Clínico San Carlos, Madrid, Spain.

Á Peñuelas (Á)

Coordinadora de Enfermería Oncológica, Hospital Universitari Vall d'Hebron, Vall d'Hebron Instituto de Oncología, Barcelona, Spain.

J M Sepúlveda (JM)

Servicio de Oncología Médica, Hospital Universitario Doce de Octubre, Madrid, Spain.

N Quer (N)

Servicio de Farmacia Hospitalaria, Instituto Catalán de Oncología, Barcelona, Spain.

N Doménech-Climent (N)

Adjunta de Enfermería, Hospital Virgen de los Lirios, Alcoy, Spain.
Universidad de Alicante, Alicante, Spain.

J A Virizuela (JA)

Servicio de Oncología Médica, Hospital Universitario Virgen Macarena, Seville, Spain.

P Beorlegui (P)

Enfermería Clínica Avanzada, Clínica Universitaria de Navarra, Pamplona, Spain.

M Q Gorgas (MQ)

Servicio de Farmacia Hospitalaria, Hospital Universitario Vall d'Hebron, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH